588 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Stock Market News For Feb 7, 2019 http://www.zacks.com/stock/news/352868/stock-market-news-for-feb-7-2019?cid=CS-ZC--352868 Feb 07, 2019 - U.S. stocks closed lower on Wednesday following disappointing earnings results from videogame companies.
Eli Lilly & Co (LLY) Q4 2019 Earnings Conference Call Transcript https://www.fool.com/investing/2019/02/06/eli-lilly-co-lly-q4-2019-earnings-conference-call.aspx?source=iedfolrf0000001 Feb 06, 2019 - LLY earnings call for the period ending December 31, 2018.
Eli Lilly and Company (LLY) CEO Dave Ricks on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4238673-eli-lilly-company-lly-ceo-dave-ricks-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Feb 06, 2019 -
Eli Lilly (LLY) Lags Q4 Earnings, Tops Sales, Cuts 2019 View http://www.zacks.com/stock/news/352407/eli-lilly-lly-lags-q4-earnings-tops-sales-cuts-2019-view?cid=CS-ZC-FT-352407 Feb 06, 2019 - Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued outlook for earnings and sales. Stock drops in pre-market trading.
Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer http://www.zacks.com/stock/news/352085/mercks-keytruda-clinches-chmp-nod-for-difficult-lung-cancer?cid=CS-ZC-FT-352085 Feb 05, 2019 - Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.
Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines http://www.zacks.com/stock/news/352006/allergan-stock-falls-as-fda-oks-botox-rival-for-frown-lines?cid=CS-ZC-FT-352006 Feb 05, 2019 - Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.
Sanofi's Myeloma Candidate Meets Goal in Phase III Study http://www.zacks.com/stock/news/352133/sanofis-myeloma-candidate-meets-goal-in-phase-iii-study?cid=CS-ZC-FT-352133 Feb 05, 2019 - Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Roche Submits sBLA to FDA for Label Expansion of Kadcyla http://www.zacks.com/stock/news/352051/roche-submits-sbla-to-fda-for-label-expansion-of-kadcyla?cid=CS-ZC-FT-352051 Feb 05, 2019 - Roche (RHHBY) submits sBLA for Kadcyla to the FDA for adjuvant treatment of patients with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.
Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy http://www.zacks.com/stock/news/351848/teva-gains-positive-chmp-opinion-for-migraine-drug-ajovy?cid=CS-ZC-FT-351848 Feb 04, 2019 - Teva (TEVA) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP), advocating a marketing approval for its new migraine medicine, Ajovy.
Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat http://www.zacks.com/stock/news/351653/novo-nordisk-nvo-q4-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-351653 Feb 01, 2019 - Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.

Pages: 1...4567891011121314...59

<<<Page 9>